Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413078 | 0.90 | LMNA (0.51) | MAPTPOLBALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3326864 | 0.88 | MAPT (0.61) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL3326035 | 0.88 | MAPT (0.52) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14618257 | 0.85 | MAPT (0.45) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14110674 | 0.83 | MAPT (0.44) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL426750 | 0.83 | CHEK1 (0.55) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL427561 | 0.83 | GBA1 (0.49) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL16844679 | 0.83 | CHEK1 (0.55) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL3330743 | 0.83 | MAPT (0.47) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL5720652 | 0.83 | MAPT (0.45) | MAPTTP53POLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7410990-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410990-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
| US-7122665-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1556140-A4 | NOVEL COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1556140-A2 | NOVEL COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040198725-A1 | A bi-heterocyclic compound e.g 3-methoxyphenyl)-{6-Morpholin-4-yl-2-[2-(pyridin-2-yloxy)-ethoxy]-9H-purin-8-yl}-amine or other derivatives useful for treating an interleukin-12 overproduction-related disorder such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis or diabetes | SYNTA PHARMACEUTICALS CORP. | 2004-10-07 | — | — | US | disclosed |
| WO-2004035740-A2 | AROMATIC BICYCLIC HETEROCYLES TO MODULATE 1L - 12 PRODUCTION | SYNTA PHARMACEUTICALS CORP. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | MAPT 238/4885TP53 1256/4885POLB 2582/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MAPT 4316/4885TP53 4162/4885POLB 3380/4885 |
| US-20040198725-A1 | A bi-heterocyclic compound e.g 3-methoxyphenyl)-{6-Morpholin-4-yl-2-[2-(pyridin-2-yloxy)-ethoxy]-9H-purin-8-yl}-amine or other derivatives useful for treating an interleukin-12 overproduction-related disorder such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis or diabetes | MSR1, NGFR, NR0B1 | MAPT 2327/4885TP53 4277/4885POLB 1077/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | MAPT 1747/4885TP53 50/4885POLB 1968/4885 |
| US-20070027151-A1 | Heterocyclic compounds | NRAS, OXER1, HCRTR2 | MAPT 4633/4885TP53 1417/4885POLB 2703/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | MAPT 4316/4885TP53 4162/4885POLB 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.